
LPGA's South Korean broadcasting partner failed to pay for 2024 and 2025 seasons
LPGA's South Korean broadcasting partner failed to pay for 2024 and 2025 seasons
The LPGA's issues with its South Korean media rights partner didn't end with a lost event. In addition to the unpaid bills that canceled the upcoming Fir Hills Seri Pak Championship, JTBC also failed to pay for broadcasting all LPGA events in 2024 and 2025. Golfweek obtained a memo sent out to LPGA players by interim commissioner Liz Moore that outlined further details, including that JTBC had not "engaged meaningfully or provided assurance of payment."
"To protect our interests, we are filing a complaint to enforce a guarantee agreement with a JTBC affiliate to recover the unpaid amounts," Moore wrote in a memo sent to players on Feb. 18.
"For now, we are not terminating our agreements and will continue honoring our obligations to avoid disruptions in tournament coverage in Korea. However, if JTBC fails to meet its broadcast commitments, we are prepared to implement alternative solutions."
With the LPGA's contract with JTBC expiring at year-end, the tour has already gone to market to explore new options.
In January, the tour canceled the Fir Hills Seri Pak Championship, scheduled for March 20-23, in Palos Verdes Estates, California, after it said an unnamed underwriter failed to pay its bills for the 2024 and 2025 events. Golfweek later confirmed JTBC as the underwriter.
JTBC's media rights deal with the LPGA dates back to the Carolyn Bivens era as commissioner, which officially went into effect in 2010, when Mike Whan was in charge. The original deal, outlined in an LPGA press release in 2009, included JTBC underwriting an event on the LPGA in Southern California as well as title sponsoring the 2009 Phoenix LPGA International.
The JTBC media rights deal is unusual in that the LPGA gets a sum of money and a set number of events, and then in turn, JTBC can recoup some of that money by selling the benefits of the event to a third party at its discretion.
The JTBC name has been attached to a number of tournaments over the years, such as the Hugel-JTBC LA Open, which later became the Hugel-Air Premia LA Open. From 2014 to 2016, the tour held the JTBC Founders Cup in Phoenix. Sometimes JTBC would appear in the title, and sometimes, as in the case of Fir Hills, it wouldn't.
The LPGA would then use JTBC's media rights money for its general operating budget.
This year's Fir Hills event, won by No. 1 Nelly Korda in 2024, was scheduled to be held at Palos Verdes Golf Club and feature a $2 million purse. The total cost of title-sponsoring the event, however, would've exceeded the value of the purse, likely around $3 million.
South Korean media rights have long been essential to the tour's health, though with top players coming from a number of different countries, the tour's media rights portfolio is now more diverse.
Late last year, Golfweek reported that LPGA was slated to lose around $2 million in 2024. That number could rise considerably in 2025.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Huawei chips are one generation behind US but firm is finding workarounds, CEO says
BEIJING (Reuters) -Huawei Technologies' chips are one generation behind those of U.S. peers but the firm is finding ways to improve performance through methods such as cluster computing, Chinese state media quoted CEO Ren Zhengfei as saying on Tuesday. The chipmaker invests 180 billion yuan ($25.07 billion) in research annually and sees promise in compound chips - or chips made from multiple elements - Ren said in an interview in the People's Daily newspaper of the governing Communist Party. The public comments are the first from Ren or Huawei about the firm's advanced chip manufacturing efforts. U.S. export controls since 2019 have prevented Huawei from accessing high-end chips and equipment to manufacture them. Huawei has since marketed its Ascend series of artificial intelligence chips which compete in China with offerings from U.S. rival Nvidia, the global leader in AI chips. The U.S. commerce department last month said use of Ascend chips would be a violation of export controls. Huawei is just one of many Chinese chipmakers, Ren said in the interview. "The United States has exaggerated Huawei's achievements. Huawei is not that great. We have to work hard to reach their evaluation," he said. "Our single chip is still behind the U.S. by a generation. We use mathematics to supplement physics, non-Moore's law to supplement Moore's law and cluster computing to supplement single chips and the results can also achieve practical conditions," he said. Cluster computing is when multiple computers work together. Moore's law refers to the speed of chip advancement. ($1 = 7.1802 Chinese yuan renminbi)


Business Upturn
2 hours ago
- Business Upturn
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) — AriBio Co., Ltd. ('AriBio'), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. Advertisement AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. 'This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide,' said Jai Jun Choung, CEO of AriBio. 'Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions.' 'We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries,' said Isabel Afonso, CEO of Arcera. 'This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs.' The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.